Chargement en cours...

Application of CRISPR/Cas9 Technology to HBV

More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (c...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Guigao Lin, Kuo Zhang, Jinming Li
Format: Artigo
Langue:Inglês
Publié: MDPI AG 2015-11-01
Collection:International Journal of Molecular Sciences
Sujets:
HBV
Accès en ligne:http://www.mdpi.com/1422-0067/16/11/25950
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!